ClinicalTrials.gg
CompletedNCT01572740Updated Feb 7, 2018Results posted

Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes

A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 23 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-02-07.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
257
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
41st of 151
257 · median 62
Started
2012
with 20 others
Phase 3
45 of 151
1 open now
Registered
57th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 41st largest by enrollment, is one of 21 that started in 2012, is one of 45 in phase 3, and was the 57th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The purpose of the trial is to investigate the efficacy and safety of liraglutide in combination with insulin therapy compared to insulin alone in Japanese subjects with type 2 diabetes mellitus. Subjects will remain on their pre-trial insulin therapy.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 257 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months
  • Current insulin therapy (basal insulin, premixed insulin or basal-bolus regimen) in addition to diet and exercise therapy for at least 12 weeks prior to trial start. Their therapy is stable and fluctuation of total daily insulin dose is within plus/minus 20% for at least 12 weeks prior to trial start and current total daily insulin dose equal to or greater than 10 (I)U/day
  • Glycosylated () between 7.5 and 11.0% (both inclusive)
  • (BMI) below 45.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as, but not limited to systemic , beta-antagonists or monoamine oxidase (MAO) inhibitors
  • Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic episode during last 12 months) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months
  • Known proliferative retinopathy or maculopathy requiring treatment according to the investigator
  • Treatment with glucagon-like peptide-1 (GLP-1) receptor agonist within 12 weeks prior to screening
  • Treatment with any oral antidiabetic drugs (OADs) within 12 weeks prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    Lira+Insulin

    Drug: liraglutide · Drug: insulin

  • Placebo comparator
    Placebo+Insulin

    Drug: placebo · Drug: insulin

Interventions

  • Liraglutide administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.

  • Drugplacebo

    Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.

  • All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16

    Estimated mean change from baseline in HbA1c after 16 Weeks of treatment.

    Time frame: Week 0, Week 16

Secondary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 36

    Estimated mean change from baseline in HbA1c after 36 Weeks of treatment

    Time frame: Week 0, Week 36

  2. Change in Fasting Plasma Glucose (FPG) From Baseline to Week 16

    Estimated mean change from baseline in FPG after 16 Weeks of treatment.

    Time frame: Week 0, Week 16

  3. Change in Fasting Plasma Glucose (FPG) From Baseline to Week 36

    Estimated mean change from baseline in FPG after 36 Weeks of treatment.

    Time frame: Week 0, Week 36

  4. Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 16

    Estimated mean change from baseline in mean PG of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 16 Weeks of treatment.

    Time frame: Week 0, Week 16

  5. Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 36

    Estimated mean change from baseline in mean PG of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 36 Weeks of treatment.

    Time frame: Week 0, Week 36

  6. Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 16

    Estimated mean change from baseline in mean prandial PG increment of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 16 Weeks of treatment.

    Time frame: Week 0, Week 16

  7. Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 36

    Estimated mean change from baseline in mean prandial PG increment of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 36 Weeks of treatment.

    Time frame: Week 0, Week 36

  8. Change in Body Weight From Baseline to Week 16

    Estimated mean change in body weight after 16 Weeks of treatment

    Time frame: Week 0, Week 16

  9. Change in Body Weight From Baseline to Week 36

    Estimated mean change in body weight after 36 Weeks of treatment

    Time frame: Week 0, Week 36

  10. Number of Adverse Events (AEs)

    An AE was defined as treatment emergent if the onset date was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

    Time frame: Week 0 to Week 36 (inclusive)

  11. Number of Confirmed Hypoglycaemic Episodes

    A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and until the last day on randomised treatment. Confirmed hypoglycaemic episode was defined as hypoglycaemic episodes categorised to severe and/or minor hypoglycaemic episodes. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or have a recorded PG \< 3.1 mmol/L (56 mg/dL). Minor: PG \< 3.1 mmol/L (56 mg/dL).

    Time frame: Week 0 to week 36 (inclusive)

08

Results

Posted May 23, 2014

Participant flow

This trial was conducted at 23 sites in Japan.

Participant flow — Overall Study
MilestoneLira + InsulinPlacebo + Insulin
Started127130
Completed121125
Not completed65
Withdrew: Adverse event11
Withdrew: Withdrawal by subject11
Withdrew: Unclassified43

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16

Estimated mean change from baseline in HbA1c after 16 Weeks of treatment.

Time frame:
Week 0, Week 16
Reported as:
Mean · percentage of glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16
percentage of glycosylated haemoglobinLira + InsulinPlacebo + Insulin
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16-1.73 ± 0.06-0.43 ± 0.06
Statistical analysis
  • Lira + Insulin vs Placebo + Insulin · ANCOVA · p = <0.0001 · Estimated treatment difference, mean: -1.30 · 95% CI -1.47 to -1.13
SecondaryChange in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 36

Estimated mean change from baseline in HbA1c after 36 Weeks of treatment

Time frame:
Week 0, Week 36
Reported as:
Mean · percentage of glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 36
percentage of glycosylated haemoglobinLira + InsulinPlacebo + Insulin
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 36-1.68 ± 0.06-0.88 ± 0.06
Statistical analysis
  • Lira + Insulin vs Placebo + Insulin · ANCOVA · p = <0.0001 · Estimated treatment difference, mean: -0.81 · 95% CI -0.99 to -0.63
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline to Week 16

Estimated mean change from baseline in FPG after 16 Weeks of treatment.

Time frame:
Week 0, Week 16
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 16
mmol/LLira + InsulinPlacebo + Insulin
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 16-1.31 ± 0.17-0.48 ± 0.17
Statistical analysis
  • Lira + Insulin vs Placebo + Insulin · ANCOVA · p = <0.0006 · Estimated treatment difference, mean: -0.83 · 95% CI -1.30 to -0.36
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline to Week 36

Estimated mean change from baseline in FPG after 36 Weeks of treatment.

Time frame:
Week 0, Week 36
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 36
mmol/LLira + InsulinPlacebo + Insulin
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 36-1.55 ± 0.16-1.29 ± 0.16
Statistical analysis
  • Lira + Insulin vs Placebo + Insulin · ANCOVA · p = 0.2511 · Estimated treatment difference, mean: -0.26 · 95% CI -0.70 to 0.18
SecondaryChange in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 16

Estimated mean change from baseline in mean PG of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 16 Weeks of treatment.

Time frame:
Week 0, Week 16
Reported as:
Mean · mmol/L
Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 16
mmol/LLira + InsulinPlacebo + Insulin
Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 16-2.41 ± 0.18-0.53 ± 0.18
Statistical analysis
  • Lira + Insulin vs Placebo + Insulin · ANCOVA · p = <0.0001 · Estimated treatment difference, mean: -1.87 · 95% CI -2.37 to -1.38
SecondaryChange in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 36

Estimated mean change from baseline in mean PG of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 36 Weeks of treatment.

Time frame:
Week 0, Week 36
Reported as:
Mean · mmol/L
Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 36
mmol/LLira + InsulinPlacebo + Insulin
Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 36-2.65 ± 0.16-1.37 ± 0.16
Statistical analysis
  • Lira + Insulin vs Placebo + Insulin · ANCOVA · p = <0.0001 · Estimated treatment difference, mean: -1.28 · 95% CI -1.73 to -0.83
SecondaryChange in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 16

Estimated mean change from baseline in mean prandial PG increment of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 16 Weeks of treatment.

Time frame:
Week 0, Week 16
Reported as:
Mean · mmol/L
Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 16
mmol/LLira + InsulinPlacebo + Insulin
Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 16-1.34 ± 0.17-0.61 ± 0.17
Statistical analysis
  • Lira + Insulin vs Placebo + Insulin · ANCOVA · p = 0.0023 · Estimated treatment difference, mean: -0.73 · 95% CI -1.20 to -0.26
SecondaryChange in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 36

Estimated mean change from baseline in mean prandial PG increment of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 36 Weeks of treatment.

Time frame:
Week 0, Week 36
Reported as:
Mean · mmol/L
Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 36
mmol/LLira + InsulinPlacebo + Insulin
Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 36-1.34 ± 0.21-0.94 ± 0.21
Statistical analysis
  • Lira + Insulin vs Placebo + Insulin · ANCOVA · p = 0.1787 · Estimated treatment difference, mean: -0.39 · 95% CI -0.97 to 0.18
SecondaryChange in Body Weight From Baseline to Week 16

Estimated mean change in body weight after 16 Weeks of treatment

Time frame:
Week 0, Week 16
Reported as:
Mean · kg
Change in Body Weight From Baseline to Week 16
kgLira + InsulinPlacebo + Insulin
Change in Body Weight From Baseline to Week 16-0.42 ± 0.14-0.28 ± 0.14
Statistical analysis
  • Lira + Insulin vs Placebo + Insulin · ANCOVA · p = 0.4806 · Estimated treatment difference, mean: -0.14 · 95% CI -0.54 to 0.25
SecondaryChange in Body Weight From Baseline to Week 36

Estimated mean change in body weight after 36 Weeks of treatment

Time frame:
Week 0, Week 36
Reported as:
Mean · kg
Change in Body Weight From Baseline to Week 36
kgLira + InsulinPlacebo + Insulin
Change in Body Weight From Baseline to Week 360.17 ± 0.200.52 ± 0.20
Statistical analysis
  • Lira + Insulin vs Placebo + Insulin · ANCOVA · p = 0.2074 · Estimated treatment difference, mean: -0.35 · 95% CI -0.91 to 0.20
SecondaryNumber of Adverse Events (AEs)

An AE was defined as treatment emergent if the onset date was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

Time frame:
Week 0 to Week 36 (inclusive)
Reported as:
Number · Events/100 years of patient exposure
Number of Adverse Events (AEs)
Events/100 years of patient exposureLira + InsulinPlacebo + Insulin
Adverse Events449350
Serious Adverse Events85
Severe Adverse Events51
Moderate Adverse Events814
Mild Adverse Events436335
SecondaryNumber of Confirmed Hypoglycaemic Episodes

A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and until the last day on randomised treatment. Confirmed hypoglycaemic episode was defined as hypoglycaemic episodes categorised to severe and/or minor hypoglycaemic episodes. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or have a recorded PG \< 3.1 mmol/L (56 mg/dL). Minor: PG \< 3.1 mmol/L (56 mg/dL).

Time frame:
Week 0 to week 36 (inclusive)
Reported as:
Number · Episodes/100 years of patient exposure
Number of Confirmed Hypoglycaemic Episodes
Episodes/100 years of patient exposureLira + InsulinPlacebo + Insulin
Number of Confirmed Hypoglycaemic Episodes146187

Adverse events

Collected over Adverse events were collected in a timeframe of 36 weeks + 7 days follow up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lira + Insulin—6/127 (4.7%)93/127 (73.2%)
Placebo + Insulin—4/130 (3.1%)69/130 (53.1%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventLira + InsulinPlacebo + Insulin
Angina pectorisCardiac disorders1/1270/130
CataractEye disorders1/1270/130
Macular fibrosisEye disorders1/1270/130
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders1/1270/130
Brain stem thrombosisNervous system disorders1/1270/130
Carotid artery stenosisNervous system disorders1/1270/130
HypertensionVascular disorders1/1270/130
Acute myocardial infarctionCardiac disorders0/1271/130
PneumoniaInfections and infestations0/1271/130
Cerebral infarctionNervous system disorders0/1271/130
Most frequent other events
Most frequent other events
EventLira + InsulinPlacebo + Insulin
NasopharyngitisInfections and infestations55/12740/130
ConstipationGastrointestinal disorders15/1272/130
DiarrhoeaGastrointestinal disorders15/1274/130
NauseaGastrointestinal disorders14/1277/130
Diabetic retinopathyEye disorders9/12713/130
HeadacheNervous system disorders8/1276/130
HypertensionVascular disorders8/1276/130
DyspepsiaGastrointestinal disorders7/1270/130
GastroenteritisInfections and infestations4/1277/130
Back painMusculoskeletal and connective tissue disorders6/1277/130

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lira + InsulinPlacebo + InsulinTotal
Mean61.3 ± 11.059.8 ± 11.360.5 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Lira + InsulinPlacebo + InsulinTotal
Female5855113
Male6975144
Body Weight
Body Weight(kg)Lira + InsulinPlacebo + InsulinTotal
Mean67.7 ± 15.265.9 ± 13.066.8 ± 14.1
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mmol/L)Lira + InsulinPlacebo + InsulinTotal
Mean8.51 ± 2.428.79 ± 2.518.65 ± 2.47
Glycosylated Haemoglobin (HbA1c)
Glycosylated Haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)Lira + InsulinPlacebo + InsulinTotal
Mean8.8 ± 0.98.8 ± 0.98.8 ± 0.9
09

Study locations

23 sites
  • Novo Nordisk Investigational Site
    Chuo-ku, Tokyo, 103 0002, Japan
  • Novo Nordisk Investigational Site
    Ebina-shi, Kanagawa, 243 0401, Japan
  • Novo Nordisk Investigational Site
    Ebina-shi, 243 0432, Japan
  • Novo Nordisk Investigational Site
    Kashiwara-shi, Osaka, 582 0005, Japan
  • Novo Nordisk Investigational Site
    Katsushika-ku, Tokyo, 125 0054, Japan
  • Novo Nordisk Investigational Site
    Koriyama-shi, Fukushima, 963 8851, Japan
  • Novo Nordisk Investigational Site
    Miyazaki-shi, 880 0034, Japan
  • Novo Nordisk Investigational Site
    Naka-shi, Ibaraki, 311 0113, Japan
  • Novo Nordisk Investigational Site
    Niigata-shi, Niigata, 950 1104, Japan
  • Novo Nordisk Investigational Site
    Nishinomiya-shi, Hygo, 662 0971, Japan
  • Novo Nordisk Investigational Site
    Oita-shi, 870 0039, Japan
  • Novo Nordisk Investigational Site
    Okawa-shi, Fukuoka, 831 0016, Japan
  • Novo Nordisk Investigational Site
    Osaka-shi, Osaka, 553 0003, Japan
  • Novo Nordisk Investigational Site
    Ota-ku, Tokyo, 144 0035, Japan
  • Novo Nordisk Investigational Site
    Oyama-shi, Tochigi, 323 0022, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 060 0062, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 062 0007, Japan
  • Novo Nordisk Investigational Site
    Sendai-shi, 980 0021, Japan
  • Novo Nordisk Investigational Site
    Shimotsuke-shi, Tochigi, 329 0433, Japan
  • Novo Nordisk Investigational Site
    Shizuoka-shi, 424 0853, Japan
  • Novo Nordisk Investigational Site
    Takatsuki-shi, Osaka, 569 1096, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 187 8510, Japan
  • Novo Nordisk Investigational Site
    Yokohama-shi, 235 0045, Japan
10

References and documents

Publications

  • Seino Y, Kaneko S, Fukuda S, Osonoi T, Shiraiwa T, Nishijima K, Bosch-Traberg H, Kaku K. Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial. J Diabetes Investig. 2016 Jul;7(4):565-73. doi: 10.1111/jdi.12457. Epub 2016 Jan 23. PubMed 27182042 ↗
  • Kaneko S, Nishijima K, Bosch-Traberg H, Kaku K, Seino Y. Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial. J Diabetes Investig. 2018 Jul;9(4):840-849. doi: 10.1111/jdi.12793. Epub 2018 Feb 5. PubMed 29277968 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2012 to primary completion in Nov 2012, 6 months.

Results were first posted in May 2014, 1 year 6 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 6 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2012
First posted
Apr 6, 2012
StartActual
Apr 5, 2012
Primary completionActual
Nov 1, 2012
CompletionActual
Mar 27, 2013
Results first posted
May 23, 2014
Last update
Feb 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01572740
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 6, 2012
Start date
Apr 5, 2012
Primary completion
Nov 1, 2012
Completion
Mar 27, 2013
Results posted
May 23, 2014
Last update
Feb 7, 2018

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion